All News MINAPHARM Pharmaceuticals

Equities

MIPH

EGS380G1C011

End-of-day quote Egyptian Exchange Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
200.3 ^EGP	0.00%		0.00%	-8.00%

Apr. 07	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 07	CI
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	23-10-05	AQ
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	23-10-04	AQ
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-28	CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	23-03-06	AQ
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI)	23-03-06	AQ
Bioventure, Minapharm Pharmaceuticals and Migentra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa	22-11-30	CI
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa	22-11-29	AQ
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa According to the agreement, Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved	22-11-29	AQ
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022	22-06-01	CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
MINAPHARM Pharmaceuticals Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	21-08-30	CI
MINAPHARM Pharmaceuticals Reports Standalone Earnings Results for the Six Months Ended June 30, 2021	21-08-11	CI
MINAPHARM Pharmaceuticals Announces Consolidated Earnings Results for the Quarter Ended March 31, 2021	21-06-15	CI
ProBioGen AG and MINAPHARM Pharmaceuticals Incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company	21-05-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News MINAPHARM Pharmaceuticals

Equities

MIPH

EGS380G1C011

All News

Filters